



PHARMACEUTICAL 2022







IKINNATE

н

A R

м

0

Ρ



PHARMACEUTICAL 2022



RealRate

Kinnate Biopharma Inc. Rank 40 of 466

The relative strengths and weaknesses of Kinnate Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kinnate Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Kinnate Biopharma Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 274%, being 196% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	258,690
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,387
Liabilities, Non-Current	0
Other Assets	107,218
Other Compr. Net Income	-515
Other Expenses	0
Other Liabilities	0
Other Net Income	348
Other Revenues	0
Property and Equipment	956
Research and Development	67,166
Selling, General and Administrative Expense	22,945

Output Variable	Value in 1000 USD
Assets	366,864
Liabilities	12,387
Expenses	90,111
Revenues	0
Stockholders Equity	354,477
Net Income	-89,763
Comprehensive Net Income	-90,020
Economic Capital Ratio	274%

